Peroxisome proliferator-activated receptors (PPARs) are activated by fatty acids and eicosanoids as well as antidyslipidemic agents. Among the receptor isotypes, PPARα demonstrates a particular role in fatty acid oxidation whereas PPARγ is known to be involved in adipocyte differentiation and lipid storage. Tesaglitazar, a dihydro cinnamate derivative, is a dual agonist of PPARα and γ that demonstrates IC50 values of 1 and 0.2 µM, respectively in ligand binding assays.{27507} At 3 µM/kg/day for three weeks, tesaglitazar has been used to reduce insulin resistance in obese Zucker rats.{27508} Furthermore, it has been investigated clinically for its potential to address disorders in glucose and lipid metabolism in patients with type 2 diabetes.{27509}
产品描述
A dual agonist of PPARα and γ (IC50s = 1 and 0.2 µM, respectively) that at 3 µM/kg/day for 3 weeks has been used to reduce insulin resistance in obese Zucker rats
